ADME-Tox & Outsourcing
Recommended Articles

The following articles and papers are useful for further understanding of the usefulness of early ADME-Tox and of using contract research organizations to increase speed and reduce costs.

Preclinical ADME-Tox

The Emerging Role of ADME in Venture Capital
VC firms are increasingly expecting in vitro and in vivo ADME Tox data not only from the firms they have funded, but also from the ones they are considering funding.

Building Better Pipelines with ADME-Tox
...the industry is pursuing strategies to uncover potential problems related to bioavailability, pharmacokinetics, or toxicity earlier in the development process—even before drug candidates enter human testing.

Introducing In Vitro ADMET Studies Earlier
Also new on the market is the ability to assess inhalation routes of drug delivery, an expedient and relatively noninvasive route of delivery for respiratory therapeutics, CNS drugs, and pain analgesics.

Drug R&D benefits from ADME/Tox technology
The advancement of ADME/Tox technologies will give rise to considerable time and cost savings as early screening and increasingly innovative solutions continue to underline the importance of this technology in drug development.

New In Vitro, Modeling Tools May Cut Tox Attrition
It used to be that the number of drugs failing preclinically due to poor pharmacokinetics hovered at about 40%, but in recent years, that has dropped to about 10%. The reason? Improved in vitro and animal models played a key role, as did more extensive use of tools like mass spectrometry and liquid chromatography/mass spectrometry (LC/MS).

The Fastest Drug Developers Also Reap the Greatest Rewards
Speed demon companies – the fastest drug developers – are consistently implementing efficient R&D practices across their portfolios. A one day speed advantage ... typically saves $37,000 in out-of-pocket development costs and nets an additional $1.1 million in daily prescription revenue for an average performing drug. Tufts reports that is because the fastest companies terminate 56% of discontinued projects in Phase I clinical development versus 36% for the slowest companies.

Drug-Discovery Outsourcing

Drug Development Partnerships, Outsourcing, Inevitable in Future
Kenneth Kaitin, director of the Tufts Center for the Study of Drug Development: "Increasingly, R & D productivity gains will depend on developers focusing on what they contribute best to the drug development value chain and partnering with organizations that provide capabilities that are too expensive to develop or maintain internally, or are outside of the company's core competencies."

CRO’s Drug R&D Contribution Has Never Been More Significant
Contract Research Organisations' (CROs) contribution to drug development has never been more crucial with faster development, earlier decisions on project failures, and higher approval success rates becoming the norm amongst outsourcing partnerships.

BMS Claims Outsourcing No Longer an Option
Outsourcing has become so paramount in a pharmaceutical’s infrastructure and drug discovery strategy that it can no longer be considered an option, according to a Bristol Myers Squibb (BMS) senior scientist.